secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168977
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for three-year terms.
- Advisory vote on named executive officer compensation passed with 42.7M for, 1.5M against, 5K abstain.
- Ratified Ernst & Young as independent auditor for FY2023 with 46.6M for, 3.2K against.
- Broker non-votes: 2.46M on director elections and say-on-pay; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/0001193125-23-168977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/d516155d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer